March 22, 2021: We support this update, strengthened by new evidence, maintaining the 2014 “B” recommendation that there is moderate certainty of a substantial net benefit for the use of low-dose aspirin as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.
Read More »On Medical Treatments & Products
NCHR’s Testimony to FDA Regarding Tanezumab for Osteoarthritis
March 24, 2021: We agree with the FDA’s assessment that the risk mitigation measures proposed for tanezumab are not likely to be feasible or effective, and there are serious risks, even after patients discontinue use.
Read More »Statement of Diana Zuckerman, Ph.D On Behalf of the National Center for Health Research Before the FDA Advisory Panel Convening to Discuss Dermal Fillers
March 23, 2021: A black box warning is needed, should be prominently displayed, and should include warnings about off-label uses as well as approved indications and well-trained providers.
Read More »Testimony of Dr. Diana Zuckerman at the FDA Advisory Committee on Johnson & Johnson COVID Vaccine
February 26, 2021: The Johnson & Johnson vaccine seems to be effective, but not proven to be more effective for moderate or severe COVID than the Pfizer or Moderna vaccines. We asked FDA to stop the hype and require studies to continue.
Read More »NCHR’s Statement on Keytruda for Early Stage Triple Negative Breast Cancer
February 9, 2021: We agree with FDA scientists that Keytruda is not proven to be effective for women with early stage triple negative breast cancer, but can cause serious health problems.
Read More »